SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-025482
Filing Date
2024-03-05
Accepted
2024-03-05 10:18:19
Documents
20
Period of Report
2024-03-05

Document Format Files

Seq Description Document Type Size
1 DEF 14A mcrb-20240305.htm   iXBRL DEF 14A 1306479
2 GRAPHIC img115650543_0.jpg GRAPHIC 117747
3 GRAPHIC img115650543_1.jpg GRAPHIC 65052
4 GRAPHIC img115650543_2.jpg GRAPHIC 11749
5 GRAPHIC img115650543_3.jpg GRAPHIC 166528
6 GRAPHIC img115650543_4.jpg GRAPHIC 170485
7 GRAPHIC img115650543_5.jpg GRAPHIC 65052
8 GRAPHIC img115650543_6.jpg GRAPHIC 491444
9 GRAPHIC img115650543_7.jpg GRAPHIC 240498
  Complete submission text file 0000950170-24-025482.txt   4983269

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mcrb-20240305.xsd EX-101.SCH 40502
21 EXTRACTED XBRL INSTANCE DOCUMENT mcrb-20240305_htm.xml XML 132205
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

IRS No.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37465 | Film No.: 24718642
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)